Get In Touch

Global PDE Inhibitors Market Introduction

Phosphodiesterase (PDE) inhibitors are therapeutic agents that target PDE isoenzymes and hinder the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate) therefore, prolonging the biological effect determined by the type of cell involved. Selective and non-selective PDE inhibitors are being discovered as possible treatments for a variety of indications such as Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), and other ailments. Phosphodiesterase super family is complex, large and represents 11 gene families from phosphodiesterase 1 to phosphodiesterase 11. Each of the phosphodiesterase families contains one or four genes. The phosphodiesterase are found in plasma membranes, cytosol, nuclear membranes, endoplasmic reticulum, and cytoskeleton.

Global PDE Inhibitors Market: Competitive Landscape

Pfizer, Inc.

Founded in 1849, Pfizer, Inc. is based in New York, U.S. It is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments including cardiovascular, oncology, neuroscience, pain, and infectious diseases. The company offers a wide range of medicines and vaccines as well as consumer health care products for the prevention and treatment of infectious and chronic diseases for all age groups. Pfizer holds the leading position in the erectile dysfunction with its brand Viagra.

Need an Overview of the Report on PDE Inhibitors Market? Ask for the Brochure here

Eli Lilly and Company

Established in 1876, Eli Lilly and Company is located in Indianapolis, Indiana, U.S. It is a multinational pharmaceuticals organization, operating in more than 160 countries, with direct presence in 27 of them. The company primarily operates through three business segments: Pharmaceuticals, Animal Health, and Health Care Management Services. In the U.S., Eli Lilly and Company distributes human pharmaceutical products, principally through independent wholesale distributors, directly to pharmacies. Its human pharmaceutical products compete globally with products of many other companies in highly competitive markets.

Bayer AG

Incorporated in 1863, Bayer is based in Leverkusen, Germany. It is a life sciences company, operating in pharmaceutical, consumer health, animal health, and agriculture domains with 150 years of history and core competences in the areas of health care and agriculture. Bayer is a group of 241 consolidated companies located in 79 countries across the world. Its consumer health segment maintains a global network of research & development facilities, with sites in the U.S., France, Germany, and China.

GlaxoSmithKline Plc

Founded in 2000, GlaxoSmithKline is based in Brentford, U.K. It is a global health care company, which is concentrated on three key business divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company has a product portfolio of established and innovative medicines. It has expertise in respiratory diseases, HIV, oncology, immune-inflammatory diseases, and rare diseases. GSK has worldwide presence in more than 150 countries, with 33% of its offices and centers in emerging markets.

Global PDE Inhibitors Market: Dynamics

Increase in Prevalence of Erectile Dysfunction to Drive PDE Inhibitors Market

The key factor driving the PDE inhibitors market is the increasing prevalence of erectile dysfunction. The etiology of erectile dysfunction can be ascribed to multiple factors, such as prostate cancer, hypertension, obesity, testosterone deficiency, diabetes mellitus, and hyperlipidemia. Furthermore, the consumption of certain substance abuse and medications can lead to erectile dysfunction. As most of the causes are related to lifestyle changes, the prevalence of erectile dysfunction is increasing globally. According to the World Health Organization (WHO), about 150 million people have been affected by erectile dysfunction and this is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.

Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “PDE Inhibitors Market” here

Increasing Burden of Chronic Diseases Expected to Fuel PDE Inhibitors Market 

Chronic diseases such as stroke, chronic obstructive pulmonary disease, heart diseases, pre-diabetes, and diabetes are the leading causes of death. These diseases contribute to a considerable portion of annual health care expenditure. Increase in health care cost related to chronic diseases is expected to result in increased adoption of the PDE4 and PDE5 inhibitors. Therefore, an increase in the health related concerns and economic burden of these diseases is likely to increase the demand for PDE inhibitors which, in turn, is likely to promote the global PDE inhibitors market during the forecast period.

Global PDE Inhibitors Market: Segmentation

The global PDE inhibitors market can be segmented depending upon:

  • Product Type
  • Route of Administration
  • Application
  • Region

Global PDE Inhibitors Market Segmentation – By Product Type

Depending on product type, the global PDE inhibitors market can be classified into:

  • PDE4 Inhibitors
  • PDE5 Inhibitors
  • Others

Global PDE Inhibitors Market Segmentation – By Route of Administration

In terms of route of administration, the global PDE inhibitors market can be divided into:

  • Oral
  • Topical
  • Others

Global PDE Inhibitors Market Segmentation – By Application

Depending on the application, the global PDE inhibitors market can be segregated into:

  • Erectile Dysfunction
  • Chronic Obstructive Pulmonary Disease
  • Others

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Pde Inhibitors Market

Pre Book